In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, ...

The Plymouth Meeting, Pa., company termed the FDA's refusal to file a short-term setback and said its long-term strategy for pitolisant in idiopathic hypersomnia is on track with its focus on a ...

Idiopathic Hypersomnia (IH) is a rare and chronic neurological disease that is characterized by excessive daytime sleepiness (EDS) despite sufficient or even long sleep time. EDS in IH cannot be ...

Harmony Biosciences received an FDA Refusal to File letter for pitolisant in idiopathic hypersomnia but plans a Phase 3 trial in Q4 2025. Q4 net product revenue reached $201M, surpassing estimates ...

Anne Imhof’s three-hour spectacle of moody youth at the Armory is sweet sorrow, full of moping and muttering. Still, almost despite itself, it points to true art. By Jason Farago and George ...

(Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) ...

March 4, 2025 • The jury cited Liu's "reverence for culture, history and nature, chronicling time and comforting users with familiarity through modern interpretations of classic Chinese ...

The best of New York for free. Sign up for our email to enjoy New York without spending a thing (as well as some options when you’re feeling flush). Our newsletter hand-delivers the best bits to ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Text-to-image AI art generators ...